Targeted therapy/chemotherapy drug-related: breast cancer: HER2 gene amplification; lung cancer: EGFR, KRAS, BRAF, HER2 gene mutation; ALK translocation, ROS1 translocation; CMET gene amplification, etc.; colorectal cancer: KRAS, NRAS, BRAF, PI3K gene mutation, microsatellite instability; gastric cancer: HER2 amplification; CMET gene amplification. Gastrointestinal mesenchymal tumor: CKIT, PDGFRA gene mutation; Glioma: 1p/19q abnormality, MGMT methylation, IDH1 gene mutation, etc. Tumor differential diagnosis: lymphoma: Ig/TCR clonal rearrangement, IGH, CCND1, CMYC, MALT1, BCL2 chromosomal translocation; soft tissue sarcoma: EWSR1, FUS, SS18, FOXO1, DDIT3 chromosomal translocation, MDM2 gene amplification; thyroid cancer: BRAF, RET gene mutation, etc. Tumor genetic related: breast cancer, ovarian cancer related: BRCA1/2 gene mutation; colorectal cancer: MLH1, MSH2 and other gene mutations; medullary thyroid cancer: RET gene mutation, etc.